LifeVantage Announces Completion of International In Vitro Study on the MB System™

Core Insights - LifeVantage Corporation has completed an international in vitro cell study on its MindBody GLP-1 System™, showing significant increases in GLP-1 hormone production [1][2] - The international formulation aims to provide the same benefits as the US version while complying with global regulatory standards [1] - The study utilized ELISA and fluorescent microscopy to assess GLP-1 production and the synergistic effects of the product's active ingredients [2] Company Overview - LifeVantage Corporation, founded in 2003 and headquartered in Lehi, Utah, specializes in nutrigenomics, focusing on how nutrition and natural compounds can enhance health [3] - The company offers a range of scientifically validated products, including the Protandim® family, TrueScience® Liquid Collagen, and the new MindBody GLP-1 System™ [3] - LifeVantage operates through independent consultants who market its products and business opportunities [3] Product Development and Market Launch - The MindBody GLP-1 System™ is set to launch internationally in March 2025, following its successful debut in the US in October 2024 [2] - Users of the US version reported a 140% average increase in GLP-1 production and improvements in food-related behaviors [2] - The company plans to share further details about the in vitro study and ongoing research at its Global Convention scheduled for April 24-26, 2025 [2]